A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

• ClinicalTrials.gov Identifier: NCT02969525
• Recruitment Status: Completed
• First Posted: November 21, 2016
• Results First Posted: November 25, 2020
• Last Update Posted: November 25, 2020
• Sponsor: UCB Biopharma S.P.R.L.
• Information provided by (Responsible Party): UCB Pharma ( UCB Biopharma S.P.R.L. )

• Study Type: Interventional
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Psoriatic Arthritis
• Interventions: Other: Placebo; Drug: Bimekizumab
• Enrollment: 206

Participant Flow

Recruitment Details	The study started to enroll patients in October 2016 and concluded in July 2018.
Pre-assignment Details	The study included a 28-Day Screening Period, followed by a Double-blind Period from Day 1 to Week 12, prior to treatment re-randomization, a Dose-blind Period, from Week 12 after the treatment re-randomization and up to Week 48 and a Safety Follow-Up (SFU) Period, post week 48. The Participant Flow refers to the Randomized Set and Dose-Blind Set.

Arm/Group Title	Placebo	BKZ 16 mg	BKZ 160 mg	BKZ 160 mg LD	BKZ 320 mg	Placebo - BKZ 160 mg	Placebo - BZK 320 mg	BKZ 16 mg - BKZ 160 mg	BZK 16 mg - BZK 320 mg	BZK 160 mg LD - BZK 160 mg	BZK 160 mg - BKZ Dose 160 mg	BKZ 320 mg - BKZ 320 mg
Arm/Group Description	Participants received Placebo during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.
Period Title: Double-Blind Period
Started	42	41	41	41	41	0	0	0	0	0	0	0
Completed Double-Blind Period	42	41	40	39	41	0	0	0	0	0	0	0
Completed Wk12 and Started Dose-Blind	40	41	40	37	41	0	0	0	0	0	0	0
Completed	40	41	40	37	41	0	0	0	0	0	0	0
Not Completed	2	0	1	4	0	0	0	0	0	0	0	0
Reason Not Completed
Adverse Event	0	0	1	1	0	0	0	0	0	0	0	0
LOW EGFR	0	0	0	1	0	0	0	0	0	0	0	0
Study medication discontinued prior Wk12	2	0	0	2	0	0	0	0	0	0	0	0
Period Title: Dose-Blind Period
Started	0	0	0	0	0	20	20	22	19	37	40	41
Completed	0	0	0	0	0	20	18	22	18	34	38	39
Not Completed	0	0	0	0	0	0	2	0	1	3	2	2
Reason Not Completed
Adverse Event	0	0	0	0	0	0	0	0	0	1	1	1
Withdrawal by Subject	0	0	0	0	0	0	2	0	1	2	0	0
Non-cooperating patient	0	0	0	0	0	0	0	0	0	0	0	1
Withdrew before Safety Follow-up visit	0	0	0	0	0	0	0	0	0	0	1	0

Baseline Characteristics

Arm/Group Title		Placebo	BKZ 16 mg	BKZ 160 mg	BKZ 160 mg LD	BKZ 320 mg	Total Title
Arm/Group Description		Participants received Placebo during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	[Not Specified]
Overall Number of Baseline Participants		42	41	41	41	41	206
Baseline Analysis Population Description		The Baseline Characteristics refer to the Full Analysis Set (FAS), which consisted of all randomized study participants who received at least 1 dose of investigational medicinal product (IMP) and had a valid measurement of the primary efficacy variable at Baseline.
Age, Categorical; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	42 participants	41 participants	41 participants	41 participants	41 participants	206 participants
	<=18 years	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%
	Between 18 and 65 years	38 90.5%	35 85.4%	40 97.6%	36 87.8%	36 87.8%	185 89.8%
	>=65 years	4 9.5%	6 14.6%	1 2.4%	5 12.2%	5 12.2%	21 10.2%
Age, Continuous; Mean (Standard Deviation); Unit of measure: Years
	Number Analyzed	42 participants	41 participants	41 participants	41 participants	41 participants	206 participants
		49.02 (12.07)	49.98 (13.56)	48.00 (11.65)	49.05 (12.99)	50.39 (12.08)	49.29 (12.39)
Sex: Female, Male; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	42 participants	41 participants	41 participants	41 participants	41 participants	206 participants
	Female	18 42.9%	17 41.5%	21 51.2%	27 65.9%	18 43.9%	101 49.0%
	Male	24 57.1%	24 58.5%	20 48.8%	14 34.1%	23 56.1%	105 51.0%
Race/Ethnicity, Customized; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	42 participants	41 participants	41 participants	41 participants	41 participants	206 participants
	Asian	1 2.4%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 0.5%
	Black	1 2.4%	1 2.4%	2 4.9%	1 2.4%	0 0.0%	5 2.4%
	White	40 95.2%	40 97.6%	39 95.1%	40 97.6%	41 100.0%	200 97.1%

Outcome Measures

1. Primary Outcome

Title	ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12
Description	The ACR50 response rate was based on 50% improvement relative to Baseline in the following measures: Tender Joint Count (TJC) based on 78 joints; Swollen Joint Count (SJC) based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by Patient's Global Assessment of Disease Activity (PGADA) Disease activity as assessed by Physician's Global Assessment of Disease Activity (PhGADA) Pain as assessed by Patient's Assessment of Arthritis Pain (PtAAP) Physical function as assessed by Health Assessment Questionnaire - Disability Index (HAQ-DI) Acute phase response as assessed by high sensitivity C-reactive protein (hs CRP).
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

The Full Analysis Set (FAS) consisted of all randomized study participants who received at least 1 dose of investigational medicinal product (IMP) and had a valid measurement of the primary efficacy variable at Baseline.

Arm/Group Title	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Arm/Group Description:	Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Overall Number of Participants Analyzed	42	41	41	41	41
Measure Type: Number; Unit of Measure: percentage of subjects
	7.1	26.8	41.5	46.3	24.4

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 16 mg (FAS), BKZ 160 mg (FAS), BKZ 160 mg LD (FAS), BKZ 320 mg (FAS)
	Comments	Statistic and p-value were calculated using a Cochran-Mantel-Haenszel test (test for non-zero correlation statistic) based on modified ridit scores and including geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure as stratification factors. The 160 loading dose arm was not considered in the dose-response because this is a mixed dose and the test is examining linear dose response.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.031
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Correlation statistic
	Estimated Value	4.6
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 16 mg (FAS)
	Comments	For differences in relation to placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Factor Necrosis (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
Statistical Test of Hypothesis	P-Value	=0.032
	Comments	The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	4.2
	Confidence Interval	(2-Sided) 95%; 1.13 to 15.23
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg (FAS)
	Comments	For differences in relation to placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Factor Necrosis (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
Statistical Test of Hypothesis	P-Value	=0.001
	Comments	The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	8.1
	Confidence Interval	(2-Sided) 95%; 2.28 to 28.74
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg LD (FAS)
	Comments	For differences in relation to placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Factor Necrosis (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	9.7
	Confidence Interval	(2-Sided) 95%; 2.73 to 34.26
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 320 mg (FAS)
	Comments	For differences in relation to placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Factor Necrosis (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
Statistical Test of Hypothesis	P-Value	=0.051
	Comments	The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.7
	Confidence Interval	(2-Sided) 95%; 1.00 to 13.68
	Estimation Comments	[Not Specified]

2. Secondary Outcome

Title	ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12
Description	The ACR20 response rate was based on 20% improvement relative to Baseline in the following measures: TJC based on 78 joints; SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA Disease activity as assessed by PhGADA Pain as assessed by PtAAP Physical function as assessed by HAQ-DI Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

Arm/Group Title	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Arm/Group Description:	Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Overall Number of Participants Analyzed	42	41	41	41	41
Measure Type: Number; Unit of Measure: percentage of subjects
	19.0	53.7	73.2	61.0	51.2

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 16 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.002
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	4.6
	Confidence Interval	(2-Sided) 95%; 1.73 to 12.39
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	11.0
	Confidence Interval	(2-Sided) 95%; 3.91 to 30.95
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg LD (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	6.2
	Confidence Interval	(2-Sided) 95%; 2.31 to 16.84
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 320 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.004
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	4.2
	Confidence Interval	(2-Sided) 95%; 1.59 to 11.35
	Estimation Comments	[Not Specified]

3. Secondary Outcome

Title	ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12
Description	The ACR70 response rate was based on 70% improvement relative to Baseline in the following measures: TJC based on 78 joints; SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA Disease activity as assessed by PhGADA Pain as assessed by PtAAP Physical function as assessed by HAQ-DI Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

Arm/Group Title	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Arm/Group Description:	Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Overall Number of Participants Analyzed	42	41	41	41	41
Measure Type: Number; Unit of Measure: percentage of subjects
	4.8	12.2	19.5	31.7	14.6

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 16 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.279
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.4
	Confidence Interval	(2-Sided) 95%; 0.50 to 11.31
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.065
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	4.1
	Confidence Interval	(2-Sided) 95%; 0.92 to 17.88
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 160 mg LD (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.006
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	7.5
	Confidence Interval	(2-Sided) 95%; 1.77 to 31.28
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo (FAS), BKZ 320 mg (FAS)
	Comments	For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.
	Type of Statistical Test	Other
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	=0.172
	Comments	No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.
	Method	Regression, Logistic
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.9
	Confidence Interval	(2-Sided) 95%; 0.63 to 13.39
	Estimation Comments	[Not Specified]

4. Secondary Outcome

Title	PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1
Description	The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

Subset of of study participants in the FAS with at least (≥) 3 percent (%) psoriasis (PSO) Body Surface Area (BSA) at Baseline (NRI).

Arm/Group Title	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Arm/Group Description:	Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Overall Number of Participants Analyzed	20	14	16	17	11
Measure Type: Number; Unit of Measure: percentage of subjects
	10.0	35.7	62.5	52.9	45.5

5. Secondary Outcome

Title	PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1
Description	The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

Subset of of study participants in the FAS with at least (≥) 3 percent (%) psoriasis (PSO) Body Surface Area (BSA) at Baseline (NRI).

Arm/Group Title	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Arm/Group Description:	Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Overall Number of Participants Analyzed	20	14	16	17	11
Measure Type: Number; Unit of Measure: percentage of subjects
	10.0	57.1	68.8	70.6	72.7

6. Secondary Outcome

Title	Percentage of Participants With at Least One Adverse Event (AE) During the Study
Description	An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
Time Frame	From Screening Period until the Safety Follow-Up Visit (up to Week 72)

Outcome Measure Data

Analysis Population Description

The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

Arm/Group Title	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Arm/Group Description:	This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).	This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.
Overall Number of Participants Analyzed	42	39	126	80
Measure Type: Number; Unit of Measure: percentage of participants
	57.1	33.33	74.6	72.5

7. Secondary Outcome

Title	Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study
Description	A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death; Is life-threatening; Requires in patient hospitalization or prolongation of existing hospitalization; Is a congenital anomaly or birth defect; Is an infection that requires treatment parenteral antibiotics; Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.
Time Frame	From Screening Period until the Safety Follow-Up Visit (up to Week 72)

Outcome Measure Data

Analysis Population Description

The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

Arm/Group Title	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Arm/Group Description:	This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).	This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.
Overall Number of Participants Analyzed	42	39	126	80
Measure Type: Number; Unit of Measure: percentage of participants
	2.4	0	6.3	0

8. Secondary Outcome

Title	Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study
Description	An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
Time Frame	From Screening Period until the Safety Follow-Up Visit (up to Week 72)

Outcome Measure Data

Analysis Population Description

The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

Arm/Group Title	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Arm/Group Description:	This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).	This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.	This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.
Overall Number of Participants Analyzed	42	39	126	80
Measure Type: Number; Unit of Measure: percentage of participants
	4.8	0	4.8	2.5

9. Secondary Outcome

Title	Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure)
Description	Diastolic and systolic blood pressure were measured in millimeters of mercury (mmHg).
Time Frame	Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: mmHg
Diastolic Blood Pressure 30 min post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		1.3 (8.9)	-1.2 (4.9)	-1.2 (5.4)	0.6 (6.1)	-0.6 (5.3)
Diastolic Blood Pressure 1 h post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		1.1 (8.8)	-2.0 (6.3)	-0.7 (8.1)	1.2 (6.7)	-1.0 (5.5)
Diastolic Blood Pressure Week 1	Number Analyzed	41 participants	39 participants	43 participants	41 participants	41 participants
		0.1 (9.6)	-0.3 (6.5)	0.6 (11.4)	-0.9 (6.6)	-0.4 (6.5)
Diastolic Blood Pressure Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.7 (10.4)	-0.7 (6.5)	-1.0 (8.9)	-2.7 (8.3)	-0.1 (9.0)
Diastolic Blood Pressure Week 4 pre-dose	Number Analyzed	41 participants	39 participants	42 participants	41 participants	41 participants
		0.0 (8.2)	-1.7 (8.4)	-1.4 (10.7)	-0.8 (7.8)	-1.3 (7.4)
Diastolic Blood Pressure Week 4 post dose	Number Analyzed	41 participants	39 participants	41 participants	40 participants	40 participants
		-2.0 (8.7)	-1.0 (7.3)	-1.2 (8.9)	-0.9 (8.3)	-1.6 (7.6)
Diastolic Blood Pressure Week 8 pre-dose	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		1.0 (8.2)	-1.3 (8.7)	0.3 (8.7)	-0.5 (7.0)	0.2 (6.9)
Diastolic Blood Pressure Week 8 post dose	Number Analyzed	41 participants	39 participants	42 participants	39 participants	41 participants
		-0.9 (9.1)	-1.1 (8.4)	0.6 (8.7)	-0.7 (7.3)	-2.2 (7.4)
Diastolic Blood Pressure Week 12 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	39 participants	41 participants
		0.2 (9.1)	-1.1 (10.4)	0.2 (8.5)	-1.5 (7.9)	-0.6 (8.2)
Diastolic Blood Pressure Week 12 post dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	41 participants
		-0.3 (9.6)	-2.0 (10.0)	0.3 (8.3)	-1.8 (7.9)	-2.6 (8.0)
Diastolic Blood Pressure Week 16 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	38 participants	41 participants
		-2.7 (9.6)	-3.5 (8.9)	-0.8 (8.6)	-1.2 (8.7)	-0.4 (7.9)
Diastolic Blood Pressure Week 16 post dose	Number Analyzed	40 participants	39 participants	39 participants	36 participants	39 participants
		-3.0 (9.1)	-1.9 (8.3)	-1.7 (9.2)	-1.1 (7.9)	-2.4 (8.7)
Diastolic Blood Pressure Week 20 pre-dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		0.5 (10.3)	-1.8 (9.0)	-0.6 (8.3)	-1.4 (8.3)	-1.8 (7.3)
Diastolic Blood Pressure Week 20 post dose	Number Analyzed	39 participants	39 participants	38 participants	36 participants	40 participants
		0.1 (9.5)	-3.1 (8.3)	-0.4 (9.2)	-3.0 (9.3)	-2.6 (7.1)
Diastolic Blood Pressure Week 24 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	36 participants	40 participants
		-0.4 (7.6)	-1.6 (7.2)	-0.7 (9.3)	1.0 (6.9)	-1.0 (6.6)
Diastolic Blood Pressure Week 24 post dose	Number Analyzed	39 participants	38 participants	38 participants	35 participants	39 participants
		-0.6 (7.5)	-1.7 (7.9)	-0.3 (8.2)	-0.3 (7.6)	-1.4 (7.9)
Diastolic Blood Pressure Week 28 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	35 participants	40 participants
		1.4 (7.9)	-0.6 (9.7)	0.9 (9.5)	-0.6 (6.9)	-0.5 (7.5)
Diastolic Blood Pressure Week 28 post dose	Number Analyzed	38 participants	39 participants	39 participants	34 participants	39 participants
		1.2 (8.7)	-2.0 (9.4)	1.2 (9.0)	-0.2 (7.1)	-1.8 (7.1)
Diastolic Blood Pressure Week 32 pre-dose	Number Analyzed	39 participants	39 participants	40 participants	35 participants	39 participants
		0.2 (8.5)	-1.7 (8.6)	1.6 (9.2)	-0.3 (9.3)	-1.2 (8.6)
Diastolic Blood Pressure Week 32 post dose	Number Analyzed	36 participants	39 participants	37 participants	34 participants	39 participants
		0.7 (10.0)	-3.0 (8.6)	0.1 (9.6)	-0.6 (8.5)	-2.1 (8.5)
Diastolic Blood Pressure Week 36 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		0.0 (8.6)	-0.6 (9.2)	1.4 (8.9)	-0.9 (7.2)	0.8 (7.5)
Diastolic Blood Pressure Week 36 post dose	Number Analyzed	37 participants	38 participants	38 participants	31 participants	38 participants
		1.6 (7.7)	-1.6 (9.2)	1.3 (9.3)	-1.7 (6.8)	-0.1 (7.1)
Diastolic Blood Pressure Week 40 pre-dose	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		0.8 (7.6)	-2.5 (9.7)	1.0 (9.5)	-1.0 (7.2)	-1.9 (6.8)
Diastolic Blood Pressure Week 40 post dose	Number Analyzed	37 participants	38 participants	40 participants	33 participants	37 participants
		0.9 (7.7)	-1.8 (9.1)	0.2 (8.3)	-0.8 (6.6)	-0.1 (7.3)
Diastolic Blood Pressure Week 44 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		1.4 (9.3)	-2.1 (7.7)	1.3 (9.2)	-0.4 (6.7)	-2.4 (10.9)
Diastolic Blood Pressure Week 44 post dose	Number Analyzed	36 participants	38 participants	40 participants	33 participants	39 participants
		2.3 (9.2)	-1.3 (7.6)	-0.7 (8.7)	-1.4 (8.1)	-1.5 (6.5)
Diastolic Blood Pressure Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		1.8 (9.2)	0.4 (9.7)	1.1 (9.1)	0.6 (8.7)	-0.8 (6.4)
Systolic Blood Pressure 30 min post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.8 (8.1)	0.5 (9.7)	-0.8 (8.2)	1.5 (8.8)	-2.5 (9.7)
Systolic Blood Pressure 1 hour post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.6 (9.4)	-2.0 (10.5)	0.2 (8.7)	1.0 (8.4)	-1.8 (7.1)
Systolic Blood Pressure Week 1	Number Analyzed	41 participants	39 participants	43 participants	41 participants	41 participants
		-1.7 (10.8)	-1.3 (10.0)	1.7 (12.9)	-2.4 (8.3)	-1.6 (11.0)
Systolic Blood Pressure Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.7 (12.9)	-0.2 (9.8)	-0.1 (13.2)	-2.7 (8.2)	-0.4 (11.9)
Systolic Blood Pressure Week 4 pre-dose	Number Analyzed	41 participants	39 participants	42 participants	41 participants	41 participants
		-2.6 (11.4)	-1.5 (10.6)	-1.0 (13.0)	-2.3 (10.5)	-2.7 (11.2)
Systolic Blood Pressure Week 4 post dose	Number Analyzed	41 participants	39 participants	41 participants	40 participants	40 participants
		-3.5 (12.1)	-0.6 (10.4)	-2.2 (11.8)	-0.6 (9.1)	-3.7 (11.3)
Systolic Blood Pressure Week 8 pre-dose	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		-2.1 (13.1)	-0.8 (10.7)	-1.1 (11.3)	-3.6 (11.7)	-1.3 (10.4)
Systolic Blood Pressure Week 8 post dose	Number Analyzed	41 participants	39 participants	42 participants	39 participants	41 participants
		-3.2 (12.6)	-1.9 (11.6)	-0.3 (11.1)	-2.8 (10.2)	-1.9 (12.0)
Systolic Blood Pressure Week 12 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	39 participants	41 participants
		-3.3 (12.4)	1.6 (13.7)	-3.1 (11.7)	-4.4 (10.8)	-2.6 (9.7)
Systolic Blood Pressure Week 12 post dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	41 participants
		-3.9 (14.1)	2.1 (11.1)	-1.9 (12.0)	-3.6 (10.1)	-2.4 (10.1)
Systolic Blood Pressure Week 16 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	38 participants	41 participants
		-3.6 (15.1)	-2.3 (12.3)	-4.3 (11.3)	-4.3 (12.5)	-2.3 (11.4)
Systolic Blood Pressure Week 16 post dose	Number Analyzed	40 participants	39 participants	39 participants	36 participants	39 participants
		-3.7 (17.1)	-2.6 (11.7)	-3.4 (12.7)	-2.7 (11.0)	-5.7 (8.5)
Systolic Blood Pressure Week 20 pre-dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		-2.0 (13.1)	-3.2 (12.5)	-2.6 (11.9)	-5.4 (9.7)	-4.5 (10.5)
Systolic Blood Pressure Week 20 post dose	Number Analyzed	39 participants	39 participants	38 participants	36 participants	40 participants
		-1.9 (14.5)	-3.2 (13.0)	-3.7 (12.2)	-7.9 (11.9)	-4.4 (9.9)
Systolic Blood Pressure Week 24 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	36 participants	40 participants
		-3.1 (10.5)	-1.1 (9.5)	-2.7 (12.3)	-3.6 (10.1)	-0.3 (10.5)
Systolic Blood Pressure Week 24 post dose	Number Analyzed	39 participants	38 participants	38 participants	35 participants	39 participants
		-2.6 (10.9)	-2.8 (10.5)	-2.2 (11.7)	-3.0 (9.7)	-1.1 (10.5)
Systolic Blood Pressure Week 28 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	35 participants	40 participants
		-0.1 (11.4)	-2.5 (12.8)	-2.5 (13.1)	0.4 (11.6)	-2.9 (11.3)
Systolic Blood Pressure Week 28 post dose	Number Analyzed	38 participants	39 participants	39 participants	34 participants	39 participants
		-1.1 (12.1)	-2.9 (11.1)	-2.6 (12.4)	-0.7 (11.9)	-4.6 (11.2)
Systolic Blood Pressure Week 32 pre-dose	Number Analyzed	39 participants	39 participants	40 participants	35 participants	39 participants
		-0.9 (13.1)	-1.5 (13.3)	-0.6 (12.4)	0.6 (11.0)	-3.7 (12.4)
Systolic Blood Pressure Week 32 post dose	Number Analyzed	36 participants	39 participants	37 participants	34 participants	39 participants
		-1.7 (12.6)	-2.2 (11.6)	0.3 (12.5)	-0.4 (11.1)	-4.8 (10.6)
Systolic Blood Pressure Week 36 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		-3.1 (11.9)	1.1 (13.9)	-0.2 (13.6)	-1.8 (11.2)	-3.2 (11.1)
Systolic Blood Pressure Week 36 post dose	Number Analyzed	37 participants	38 participants	38 participants	31 participants	38 participants
		-0.6 (11.1)	1.3 (12.6)	-0.5 (12.4)	-3.8 (10.8)	-3.8 (11.4)
Systolic Blood Pressure Week 40 pre-dose	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		-3.3 (12.1)	-3.1 (11.4)	-1.6 (12.9)	-4.0 (9.5)	-1.2 (11.0)
Systolic Blood Pressure Week 40 post dose	Number Analyzed	37 participants	38 participants	40 participants	33 participants	37 participants
		-2.3 (11.7)	-0.4 (12.7)	-1.2 (13.8)	-3.2 (11.6)	-2.2 (9.6)
Systolic Blood Pressure Week 44 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		-2.8 (12.3)	-2.8 (9.9)	0.0 (13.1)	-5.1 (9.9)	-3.9 (10.3)
Systolic Blood Pressure Week 44 post dose	Number Analyzed	36 participants	38 participants	40 participants	33 participants	39 participants
		-1.8 (14.5)	-1.2 (9.5)	-0.6 (10.4)	-4.6 (10.3)	-3.8 (10.5)
Systolic Blood Pressure Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		-1.1 (14.0)	-0.1 (12.5)	-0.1 (12.6)	-2.8 (11.5)	-5.2 (9.6)

10. Secondary Outcome

Title	Changes From Baseline in Vital Signs During the Study (Pulse Rate)
Description	Pulse rate was measured in beats per minute (beats/min).
Time Frame	Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: beats/min
30 min post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.4 (5.4)	-0.8 (5.6)	-1.5 (7.2)	-2.3 (7.5)	-1.1 (7.2)
1 hour post dose	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.3 (6.7)	1.0 (11.3)	-0.8 (7.6)	-0.8 (8.1)	-0.4 (7.0)
Week 1	Number Analyzed	41 participants	39 participants	43 participants	41 participants	41 participants
		2.9 (8.3)	-1.5 (7.5)	-0.7 (7.1)	0.6 (8.9)	-0.8 (9.0)
Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		1.2 (6.4)	-1.7 (5.7)	-0.7 (7.9)	-1.0 (9.1)	-0.4 (6.9)
Week 4 pre-dose	Number Analyzed	41 participants	39 participants	42 participants	41 participants	41 participants
		-0.2 (5.3)	-2.1 (6.9)	-1.9 (8.1)	0.1 (9.8)	-1.0 (6.6)
Week 4 post dose	Number Analyzed	41 participants	39 participants	41 participants	40 participants	40 participants
		0.4 (8.6)	-2.6 (6.6)	-2.7 (9.5)	-0.5 (9.4)	-1.1 (6.2)
Week 8 pre-dose	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		0.9 (6.5)	-0.6 (8.0)	-1.6 (8.6)	0.8 (6.9)	-1.3 (8.2)
Week 8 post dose	Number Analyzed	41 participants	39 participants	42 participants	39 participants	41 participants
		-0.1 (6.9)	-1.3 (8.6)	-1.9 (8.6)	0.0 (8.5)	-2.3 (8.3)
Week 12 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	39 participants	41 participants
		1.1 (10.2)	-2.2 (8.5)	-2.9 (10.5)	-1.7 (9.5)	-1.1 (8.4)
Week 12 post dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	41 participants
		-0.6 (8.8)	-3.3 (8.8)	-3.6 (9.4)	-2.1 (9.7)	-2.0 (7.8)
Week 16 pre-dose	Number Analyzed	42 participants	39 participants	42 participants	38 participants	41 participants
		-0.2 (8.5)	-2.1 (5.8)	-2.9 (8.0)	-1.9 (10.1)	-1.3 (7.2)
Week 16 post dose	Number Analyzed	40 participants	39 participants	39 participants	36 participants	39 participants
		-0.1 (9.9)	-3.5 (5.5)	-3.7 (9.7)	-2.1 (9.8)	-2.2 (7.3)
Week 20 pre-dose	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		-0.1 (10.3)	-2.4 (7.0)	-1.7 (10.3)	0.0 (9.0)	-1.2 (9.0)
Week 20 post dose	Number Analyzed	39 participants	39 participants	38 participants	36 participants	40 participants
		-0.7 (6.8)	-2.3 (7.8)	-2.1 (9.7)	-0.1 (8.5)	-1.3 (8.9)
Week 24 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	36 participants	40 participants
		-0.5 (7.9)	-2.0 (8.1)	-2.8 (10.4)	-0.7 (7.3)	-1.2 (7.8)
Week 24 post dose	Number Analyzed	39 participants	38 participants	38 participants	35 participants	39 participants
		-0.9 (7.8)	-2.9 (8.5)	-3.0 (9.6)	-1.3 (6.9)	-2.5 (7.1)
Week 28 pre-dose	Number Analyzed	39 participants	39 participants	41 participants	35 participants	40 participants
		1.9 (9.7)	-2.1 (10.0)	0.0 (9.3)	-0.5 (11.2)	0.2 (8.3)
Week 28 post dose	Number Analyzed	38 participants	39 participants	39 participants	34 participants	39 participants
		1.8 (7.5)	-3.0 (9.4)	-0.5 (8.5)	-0.8 (10.0)	0.0 (7.5)
Week 32 pre-dose	Number Analyzed	39 participants	39 participants	40 participants	35 participants	39 participants
		3.3 (10.0)	-0.9 (7.9)	-2.0 (9.2)	-1.2 (10.6)	-0.3 (7.8)
Week 32 post dose	Number Analyzed	36 participants	39 participants	37 participants	34 participants	39 participants
		3.3 (8.4)	-0.8 (7.8)	-3.0 (9.5)	-1.9 (9.6)	-2.0 (8.8)
Week 36 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		0.7 (8.5)	0.2 (7.5)	-2.6 (8.6)	-2.6 (10.2)	-0.5 (9.7)
Week 36 post dose	Number Analyzed	37 participants	38 participants	38 participants	31 participants	38 participants
		1.1 (7.6)	-0.8 (8.2)	-3.0 (9.8)	-2.5 (8.2)	-1.4 (9.6)
Week 40 pre-dose	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		2.7 (10.3)	-0.5 (8.8)	1.0 (10.1)	-1.7 (7.6)	2.0 (9.4)
Week 40 post dose	Number Analyzed	37 participants	38 participants	40 participants	33 participants	37 participants
		0.9 (8.3)	-1.7 (8.3)	0.0 (8.9)	-2.0 (8.4)	0.5 (9.1)
Week 44 pre-dose	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		2.2 (8.9)	-1.6 (6.9)	-0.4 (10.1)	-1.4 (8.2)	0.7 (9.7)
Week 44 post dose	Number Analyzed	36 participants	38 participants	40 participants	33 participants	38 participants
		2.9 (6.9)	-1.7 (8.0)	-0.5 (11.0)	-2.8 (7.7)	-0.2 (10.3)
Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		2.0 (8.9)	-3.7 (7.8)	-2.5 (10.4)	-4.2 (9.5)	-3.1 (9.5)

11. Secondary Outcome

Title	Changes From Baseline in Body Weight During the Study
Description	Body weight was measured in kilograms.
Time Frame	Baseline, Week 12, Week 24, Week 36 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Overall number of participants analyzed include only those for whom body weight was measured and analyzed during the study.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		41	39	43	38	41
Mean (Standard Deviation); Unit of Measure: kilograms
Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.14 (3.38)	-0.87 (3.12)	0.21 (1.78)	-0.38 (1.80)	-0.04 (2.39)
Week 24	Number Analyzed	39 participants	38 participants	41 participants	36 participants	40 participants
		0.33 (4.10)	-0.03 (3.48)	-0.07 (2.63)	-0.13 (2.37)	-0.39 (3.73)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		0.32 (5.15)	-0.14 (2.90)	0.27 (3.42)	0.15 (2.36)	-0.04 (4.19)
Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		0.21 (4.42)	0.45 (3.41)	0.80 (3.84)	-0.14 (3.32)	0.11 (4.24)

12. Secondary Outcome

Title	Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR)
Description	Electrocardiogram (ECG) intervals (QTcB= QT interval corrected for heart rate (Bazett's formula); QTcF= QT interval corrected for heart rate (Fridericia's formula)) were measured in milliseconds.
Time Frame	Baseline, Week 12 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Overall number of participants analyzed include only those for whom electrocardiogram data was measured and analyzed during the study.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		40	38	42	36	41
Mean (Standard Deviation); Unit of Measure: msec
QTcB Week 12	Number Analyzed	38 participants	36 participants	42 participants	34 participants	40 participants
		3.4 (32.7)	-2.8 (29.9)	-5.6 (41.8)	1.5 (18.2)	-1.9 (31.4)
QTcB Week 48	Number Analyzed	35 participants	37 participants	40 participants	31 participants	39 participants
		-2.5 (34.8)	-5.8 (36.5)	-5.9 (22.2)	-4.7 (21.0)	-5.7 (27.7)
QTcF Week 12	Number Analyzed	37 participants	32 participants	35 participants	32 participants	39 participants
		4.5 (27.5)	-2.5 (22.4)	-2.2 (14.2)	-0.5 (17.0)	-3.0 (18.8)
QTcF Week 48	Number Analyzed	35 participants	32 participants	34 participants	29 participants	38 participants
		-0.1 (30.7)	-6.1 (31.4)	-0.2 (15.6)	-2.2 (20.0)	4.6 (44.6)
PR Week 12	Number Analyzed	39 participants	37 participants	42 participants	36 participants	41 participants
		-1.7 (23.3)	-1.0 (23.7)	-19.6 (102.1)	3.2 (18.2)	-9.5 (32.3)
PR Week 48	Number Analyzed	37 participants	38 participants	40 participants	33 participants	40 participants
		2.6 (33.7)	17.5 (128.8)	4.0 (163.0)	0.8 (18.9)	-2.8 (26.5)
QRS Week 12	Number Analyzed	40 participants	38 participants	42 participants	36 participants	41 participants
		2.6 (22.3)	-2.9 (10.8)	-1.8 (7.6)	-0.2 (5.4)	6.1 (42.8)
QRS Week 48	Number Analyzed	38 participants	38 participants	40 participants	33 participants	40 participants
		5.6 (21.4)	-1.5 (16.1)	-4.0 (13.0)	0.6 (16.2)	0.1 (18.7)
QT Week 12	Number Analyzed	40 participants	38 participants	42 participants	36 participants	41 participants
		-2.0 (46.6)	1.7 (34.0)	9.5 (21.4)	3.8 (25.6)	11.5 (80.8)
QT Week 48	Number Analyzed	38 participants	38 participants	40 participants	33 participants	40 participants
		-0.7 (33.4)	3.1 (29.9)	3.9 (22.8)	5.4 (26.7)	0.7 (31.6)
RR Week 12	Number Analyzed	39 participants	36 participants	42 participants	34 participants	41 participants
		3.3 (99.3)	-22.5 (212.6)	75.8 (179.3)	11.0 (125.1)	-17.0 (182.1)
RR Week 48	Number Analyzed	37 participants	36 participants	40 participants	31 participants	40 participants
		-0.6 (116.1)	11.9 (187.1)	65.2 (139.0)	44.3 (124.0)	25.1 (148.5)

13. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)
Description	Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils were measured in number of white blood cells per liter (10^9/L).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: 10^9 white blood cells per liter
Basophils Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		0.000 (0.0387)	0.000 (0.0329)	-0.002 (0.0408)	0.007 (0.0264)	0.008 (0.0350)
Basophils Week 2	Number Analyzed	42 participants	38 participants	43 participants	41 participants	41 participants
		0.002 (0.0269)	0.003 (0.0283)	0.000 (0.0488)	0.000 (0.0316)	0.005 (0.0384)
Basophils Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		0.002 (0.0474)	0.005 (0.0324)	-0.007 (0.0463)	0.005 (0.0312)	0.005 (0.0312)
Basophils Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-0.002 (0.0353)	0.000 (0.0229)	-0.005 (0.0384)	0.003 (0.0367)	0.002 (0.0418)
Basophils Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.002 (0.0353)	0.003 (0.0280)	-0.002 (0.0462)	0.000 (0.0329)	0.010 (0.0374)
Basophils Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		0.010 (0.0431)	0.005 (0.0324)	-0.007 (0.0463)	0.000 (0.0329)	0.008 (0.0417)
Basophils Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	39 participants
		-0.003 (0.0362)	0.003 (0.0362)	0.000 (0.0500)	0.005 (0.0329)	0.000 (0.0397)
Basophils Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		0.000 (0.0397)	0.005 (0.0324)	-0.003 (0.0530)	0.008 (0.0368)	0.005 (0.0389)
Basophils Week 28	Number Analyzed	39 participants	38 participants	40 participants	35 participants	40 participants
		0.005 (0.0394)	0.000 (0.0329)	0.008 (0.0526)	0.011 (0.0323)	0.005 (0.0450)
Basophils Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		0.000 (0.0324)	0.005 (0.0320)	-0.010 (0.0441)	0.009 (0.0379)	0.010 (0.0384)
Basophils Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		0.000 (0.0408)	0.003 (0.0283)	-0.002 (0.0474)	0.012 (0.0415)	0.013 (0.0409)
Basophils Week 40	Number Analyzed	36 participants	38 participants	40 participants	34 participants	38 participants
		0.003 (0.0506)	0.005 (0.0399)	-0.010 (0.0379)	0.006 (0.0343)	0.000 (0.0403)
Basophils Week 44	Number Analyzed	36 participants	37 participants	41 participants	34 participants	36 participants
		0.006 (0.0410)	0.003 (0.0372)	0.000 (0.0387)	0.006 (0.0422)	0.000 (0.0338)
Basophils Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		-0.005 (0.0462)	0.003 (0.291)	-0.010 (0.0441)	0.006 (0.0354)	0.000 (0.0324)
Eosinophils Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		0.010 (0.0860)	0.016 (0.0718)	-0.002 (0.0801)	-0.005 (0.0999)	0.017 (0.0636)
Eosinophils Week 2	Number Analyzed	42 participants	38 participants	43 participants	41 participants	41 participants
		0.005 (0.0731)	0.013 (0.0777)	0.002 (0.0913)	0.002 (0.0880)	0.029 (0.0929)
Eosinophils Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		0.002 (0.0987)	0.016 (0.0594)	0.002 (0.0780)	0.005 (0.0999)	0.027 (0.0895)
Eosinophils Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		0.024 (0.0969)	-0.003 (0.0707)	0.000 (0.1000)	0.008 (0.0941)	0.005 (0.0669)
Eosinophils Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.020 (0.0954)	0.010 (0.0882)	0.002 (0.0831)	-0.026 (0.1155)	0.017 (0.0704)
Eosinophils Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		0.045 (0.1253)	0.021 (0.0935)	0.010 (0.0759)	-0.005 (0.1559)	0.033 (0.0829)
Eosinophils Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	39 participants
		0.036 (0.1038)	0.026 (0.1186)	0.024 (0.1157)	-0.014 (0.1228)	0.038 (0.0935)
Eosinophils Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		0.031 (0.1301)	0.013 (0.0844)	0.058 (0.2111)	-0.019 (0.1238)	0.037 (0.1192)
Eosinophils Week 28	Number Analyzed	39 participants	38 participants	40 participants	35 participants	40 participants
		0.036 (0.0986)	0.018 (0.0926)	0.053 (0.1826)	-0.000 (0.1213)	0.025 (0.0870)
Eosinophils Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		0.049 (0.1502)	0.033 (0.0838)	0.020 (0.1418)	0.024 (0.1577)	0.041 (0.1141)
Eosinophils Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		0.054 (0.1726)	0.018 (0.0955)	0.022 (0.0909)	0.027 (0.1526)	0.015 (0.0961)
Eosinophils Week 40	Number Analyzed	36 participants	38 participants	40 participants	34 participants	38 participants
		0.050 (0.1444)	0.018 (0.0865)	0.018 (0.0958)	0.015 (0.1971)	0.039 (0.1128)
Eosinophils Week 44	Number Analyzed	36 participants	37 participants	41 participants	34 participants	36 participants
		0.072 (0.1523)	0.019 (0.0908)	0.024 (0.0994)	-0.009 (0.1798)	0.006 (0.0893)
Eosinophils Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		0.045 (0.1811)	0.006 (0.0754)	0.023 (0.0891)	0.009 (0.2833)	-0.005 (0.0857)
Leukocytes Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.271 (1.1885)	-0.597 (1.1490)	-0.656 (1.2593)	-1.029 (1.6496)	-0.285 (1.6896)
Leukocytes Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.157 (1.3195)	-0.131 (2.1769)	-0.309 (1.3735)	-0.954 (2.0441)	-0.322 (1.5501)
Leukocytes Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-0.049 (1.1938)	-0.411 (1.1988)	-0.336 (1.5088)	-1.017 (1.9397)	-0.656 (1.4264)
Leukocytes Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		0.429 (1.7036)	-0.333 (1.4014)	-0.185 (1.2889)	-1.071 (1.9639)	-0.629 (1.5489)
Leukocytes Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.190 (1.6223)	-0.438 (1.3854)	-0.495 (1.6904)	-0.997 (2.1806)	-0.634 (1.6084)
Leukocytes Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-0.400 (1.5616)	-0.839 (1.8179)	-0.590 (1.4668)	-1.318 (2.3324)	-0.293 (1.8427)
Leukocytes Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	40 participants
		-0.936 (1.2756)	-1.100 (1.5599)	-0.432 (1.3032)	-0.932 (2.2832)	-0.455 (1.7116)
Leukocytes Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-1.251 (1.3888)	-0.884 (1.7768)	-0.495 (1.4216)	-1.119 (2.2807)	-0.765 (1.8691)
Leukocytes Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.700 (1.8180)	-0.316 (2.3086)	-0.100 (1.4942)	-0.894 (1.7119)	-0.342 (1.5683)
Leukocytes Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.762 (1.4273)	-0.862 (2.0091)	-0.330 (1.5750)	-0.918 (2.6184)	-0.505 (1.4800)
Leukocytes Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		-0.541 (1.5971)	-0.974 (1.7389)	-0.366 (1.4549)	-1.082 (2.3389)	-0.126 (2.2565)
Leukocytes Week 40	Number Analyzed	36 participants	38 participants	41 participants	34 participants	38 participants
		-0.783 (1.7693)	-0.826 (1.5942)	-0.437 (1.7878)	-1.226 (2.3856)	-0.266 (1.7976)
Leukocytes Week 44	Number Analyzed	37 participants	37 participants	41 participants	34 participants	36 participants
		-1.065 (1.6070)	-0.978 (1.8151)	-0.537 (1.5641)	-1.032 (2.1585)	-0.825 (1.8917)
Leukocytes Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		-0.739 (1.7774)	-0.869 (1.7109)	-0.473 (1.7104)	-1.225 (2.5952)	-0.777 (1.8593)
Lymphocytes Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.083 (0.5074)	-0.024 (0.4142)	0.044 (0.5039)	-0.017 (0.4189)	0.020 (0.3006)
Lymphocytes Week 2	Number Analyzed	42 participants	38 participants	43 participants	41 participants	41 participants
		0.105 (0.3246)	0.026 (0.4137)	0.021 (0.6006)	0.007 (0.3643)	0.161 (0.4277)
Lymphocytes Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		0.037 (0.4386)	0.024 (0.3259)	0.010 (0.6003)	-0.032 (0.3996)	0.095 (0.3263)
Lymphocytes Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		0.120 (0.3776)	0.054 (0.3783)	0.063 (0.5928)	0.053 (0.4980)	0.129 (0.3939)
Lymphocytes Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.041 (0.3647)	0.051 (0.4167)	0.000 (0.5640)	-0.047 (0.3703)	0.061 (0.3301)
Lymphocytes Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		0.052 (0.5567)	0.071 (0.3571)	0.026 (0.5539)	-0.029 (0.4991)	0.135 (0.4197)
Lymphocytes Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	39 participants
		0.003 (0.4934)	0.008 (0.3970)	0.149 (0.4675)	-0.035 (0.4566)	0.126 (0.4216)
Lymphocytes Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-0.041 (0.3905)	0.050 (0.3630)	0.048 (0.4455)	-0.036 (0.3788)	0.053 (0.3974)
Lymphocytes Week 28	Number Analyzed	39 participants	38 participants	40 participants	35 participants	40 participants
		0.036 (0.5869)	0.105 (0.3594)	0.210 (0.5999)	0.103 (0.5544)	0.172 (0.3776)
Lymphocytes Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.000 (0.5109)	0.103 (0.4233)	0.083 (0.6524)	0.112 (0.5056)	0.146 (0.3966)
Lymphocytes Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		0.078 (0.4894)	0.039 (0.4227)	0.134 (0.5673)	0.103 (0.5491)	0.118 (0.3810)
Lymphocytes Week 40	Number Analyzed	36 participants	38 participants	40 participants	34 participants	38 participants
		0.139 (0.4871)	0.168 (0.4281)	0.120 (0.6018)	0.038 (0.4335)	0.176 (0.3709)
Lymphocytes Week 44	Number Analyzed	36 participants	37 participants	41 participants	34 participants	36 participants
		-0.008 (0.5390)	0.105 (0.4136)	0.124 (0.5366)	0.115 (0.4881)	0.153 (0.4462)
Lymphocytes Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		0.066 (0.5313)	0.103 (0.3645)	0.078 (0.5041)	0.019 (0.3763)	0.072 (0.3755)
Monocytes Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		0.007 (0.2184)	-0.008 (0.1477)	-0.012 (0.1679)	-0.088 (0.2315)	-0.027 (0.1724)
Monocytes Week 2	Number Analyzed	42 participants	38 participants	43 participants	41 participants	41 participants
		0.076 (0.1358)	-0.011 (0.1673)	0.014 (0.1897)	-0.095 (0.2701)	-0.010 (0.1882)
Monocytes Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		0.032 (0.1588)	-0.021 (0.1473)	-0.040 (0.1862)	-0.066 (0.2404)	-0.085 (0.1459)
Monocytes Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		0.059 (0.1910)	-0.041 (0.1743)	0.005 (0.1580)	-0.103 (0.2520)	-0.071 (0.1834)
Monocytes Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.020 (0.1913)	-0.031 (0.1608)	-0.033 (0.1686)	-0.105 (0.2630)	-0.059 (0.1414)
Monocytes Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-0.007 (0.1629)	-0.050 (0.1673)	-0.024 (0.1265)	-0.079 (0.2384)	-0.043 (0.1752)
Monocytes Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	39 participants
		-0.008 (0.1783)	-0.041 (0.1534)	-0.015 (0.1509)	-0.081 (0.2448)	-0.003 (0.1899)
Monocytes Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-0.026 (0.1292)	-0.034 (0.1361)	0.003 (0.1476)	-0.056 (0.2602)	-0.027 (0.1921)
Monocytes Week 28	Number Analyzed	39 participants	38 participants	40 participants	35 participants	40 participants
		0.026 (0.2087)	0.042 (0.1981)	0.055 (0.1724)	-0.029 (0.2729)	-0.012 (0.1911)
Monocytes Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		0.064 (0.2356)	-0.005 (0.1731)	-0.003 (0.1271)	-0.035 (0.2684)	0.010 (0.1744)
Monocytes Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		0.054 (0.1626)	-0.024 (0.1792)	0.032 (0.1404)	-0.036 (0.2644)	0.049 (0.2327)
Monocytes Week 40	Number Analyzed	36 participants	38 participants	40 participants	34 participants	38 participants
		0.053 (0.1647)	0.008 (0.1323)	0.020 (0.1636)	-0.059 (0.2830)	-0.018 (0.1504)
Monocytes Week 44	Number Analyzed	36 participants	37 participants	41 participants	34 participants	36 participants
		0.019 (0.1939)	-0.008 (0.1588)	0.044 (0.1644)	-0.032 (0.2446)	-0.019 (0.2202)
Monocytes Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		0.021 (0.2145)	0.000 (0.1707)	-0.013 (0.1399)	-0.078 (0.2511)	-0.077 (0.1709)
Neutrophils Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.200 (1.0959)	-0.558 (0.9627)	-0.693 (1.2971)	-0.934 (1.4768)	-0.325 (1.5720)
Neutrophils Week 2	Number Analyzed	42 participants	38 participants	43 participants	41 participants	41 participants
		-0.026 (1.1945)	-0.418 (1.1627)	-0.337 (1.3109)	-0.880 (1.8457)	-0.537 (1.3989)
Neutrophils Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-0.102 (1.0044)	-0.405 (1.1246)	-0.290 (1.3463)	-0.924 (1.9975)	-0.732 (1.4028)
Neutrophils Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		0.249 (1.5358)	-0.346 (1.2640)	-0.256 (1.3898)	-1.021 (1.7129)	-0.717 (1.4589)
Neutrophils Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		0.117 (1.5103)	-0.456 (1.1227)	-0.458 (1.6879)	-0.832 (2.2192)	-0.673 (1.3887)
Neutrophils Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-0.490 (1.6866)	-0.879 (1.5752)	-0.617 (1.6027)	-1.203 (2.2840)	-0.448 (1.6816)
Neutrophils Week 20	Number Analyzed	39 participants	39 participants	41 participants	37 participants	39 participants
		-0.972 (1.2085)	-1.069 (1.4219)	-0.595 (1.4319)	-0.827 (2.2663)	-0.618 (1.5716)
Neutrophils Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-1.210 (1.4067)	-0.895 (1.6288)	-0.593 (1.5309)	-1.011 (2.2968)	-0.850 (1.6461)
Neutrophils Week 28	Number Analyzed	39 participants	38 participants	40 participants	35 participants	40 participants
		-0.774 (1.8189)	-0.484 (2.2620)	-0.555 (1.2608)	-0.949 (1.7676)	-0.568 (1.3889)
Neutrophils Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.869 (1.2796)	-0.969 (1.8241)	-0.433 (1.7889)	-1.038 (2.4800)	-0.718 (1.4299)
Neutrophils Week 36	Number Analyzed	37 participants	38 participants	41 participants	33 participants	39 participants
		-0.722 (1.6422)	-0.992 (1.6583)	-0.541 (1.5519)	-1.185 (2.1881)	-0.354 (2.1441)
Neutrophils Week 40	Number Analyzed	36 participants	38 participants	40 participants	34 participants	38 participants
		-1.006 (1.7393)	-0.992 (1.4740)	-0.575 (1.9567)	-1.229 (2.4065)	-0.495 (1.5857)
Neutrophils Week 44	Number Analyzed	36 participants	37 participants	41 participants	34 participants	36 participants
		-0.978 (1.2444)	-1.086 (1.6049)	-0.717 (1.6966)	-1.109 (2.2673)	-0.983 (1.6556)
Neutrophils Week 48	Number Analyzed	38 participants	36 participants	40 participants	32 participants	39 participants
		-0.861 (1.6858)	-0.939 (1.5670)	-0.558 (1.7944)	-1.178 (2.6503)	-0.805 (1.6631)

14. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)
Description	Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: g/L
Ery. mean corpuscular HGB Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-2.293 (8.4594)	0.789 (8.9719)	-1.860 (8.0551)	0.927 (9.1088)	1.200 (12.2395)
Ery. mean corpuscular HGB Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-2.310 (7.9923)	2.564 (9.8216)	0.465 (8.4778)	0.707 (8.6263)	2.854 (10.1822)
Ery. mean corpuscular HGB Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-3.927 (10.0633)	1.474 (10.5849)	-2.500 (11.5045)	-0.878 (9.4026)	1.756 (11.8697)
Ery. mean corpuscular HGB Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-5.195 (11.7158)	-1.897 (11.3249)	-3.780 (10.7576)	-3.079 (10.7033)	0.610 (12.7493)
Ery. mean corpuscular HGB Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		-7.927 (14.6704)	-3.179 (13.4122)	-3.907 (11.5404)	-2.684 (9.4099)	1.732 (13.3959)
Ery. mean corpuscular HGB Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-6.286 (12.3393)	-3.000 (14.5751)	-5.262 (12.1917)	-1.026 (11.6816)	-0.700 (16.1026)
Ery. mean corpuscular HGB Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		-5.050 (12.8102)	0.923 (11.8108)	-1.902 (12.8078)	0.919 (8.7349)	0.200 (16.1725)
Ery. mean corpuscular HGB Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		1.000 (10.9232)	4.132 (10.3849)	-0.625 (14.6685)	4.583 (11.3121)	4.250 (13.4064)
Ery. mean corpuscular HGB Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		2.179 (10.3285)	4.658 (9.6906)	1.707 (9.9505)	4.400 (13.7524)	6.150 (12.5382)
Ery. mean corpuscular HGB Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		6.308 (9.7796)	10.231 (9.5957)	4.850 (11.3692)	7.971 (12.3497)	10.462 (12.9855)
Ery. mean corpuscular HGB Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		5.500 (9.7779)	10.921 (10.2229)	2.732 (12.4097)	6.788 (12.2034)	9.462 (12.7998)
Ery. mean corpuscular HGB Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		3.108 (9.8736)	8.237 (12.0706)	4.976 (11.5639)	9.088 (11.5480)	9.079 (11.5393)
Ery. mean corpuscular HGB Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		6.297 (10.6975)	7.289 (12.6254)	3.415 (12.6293)	6.353 (14.3038)	9.278 (12.8076)
Ery. mean corpuscular HGB Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		5.079 (10.4916)	7.216 (9.3812)	2.122 (11.8769)	5.394 (12.9300)	8.250 (11.3448)
Hemoglobin Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-4.854 (5.6726)	0.000 (5.6569)	1.302 (5.1480)	0.512 (6.0462)	-0.875 (4.8368)
Hemoglobin Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-4.810 (6.5154)	-0.359 (5.2339)	0.070 (6.5915)	-1.561 (6.7047)	0.317 (5.3499)
Hemoglobin Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-4.390 (7.5162)	0.895 (7.6434)	0.881 (6.4551)	0.512 (5.7189)	1.195 (5.8916)
Hemoglobin Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-4.561 (7.0995)	0.308 (7.0865)	2.195 (7.7628)	0.553 (6.8010)	1.195 (7.4439)
Hemoglobin Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		-5.220 (6.7879)	0.692 (7.7601)	2.488 (7.6512)	0.868 (7.3344)	2.488 (8.2344)
Hemoglobin Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-1.619 (6.4768)	2.579 (8.3880)	1.524 (8.7853)	1.737 (7.3547)	3.125 (7.7400)
Hemoglobin Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		-0.400 (7.3233)	2.667 (8.6764)	2.268 (6.9822)	1.892 (7.6186)	2.925 (7.7207)
Hemoglobin Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		0.564 (8.1879)	3.658 (9.0622)	4.075 (8.0714)	2.000 (6.6462)	3.425 (6.2834)
Hemoglobin Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-1.513 (8.0259)	3.342 (8.9511)	3.122 (8.6261)	0.857 (7.2645)	3.400 (8.6730)
Hemoglobin Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.282 (8.2684)	4.487 (8.3094)	4.300 (9.4032)	2.118 (7.4254)	5.615 (8.6378)
Hemoglobin Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		0.947 (9.1738)	6.053 (8.1405)	4.293 (9.5766)	3.818 (7.3334)	4.949 (8.4851)
Hemoglobin Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		1.432 (9.1090)	5.868 (8.7863)	4.317 (9.6552)	3.618 (7.8277)	4.132 (7.7987)
Hemoglobin Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		1.486 (10.1040)	5.000 (9.2998)	3.659 (9.1750)	4.912 (8.5895)	4.722 (8.5511)
Hemoglobin Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		2.474 (9.7002)	5.270 (9.1974)	3.780 (9.9210)	4.030 (9.2550)	4.725 (7.3554)

15. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB))
Description	Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: picograms (pg)
Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.073 (0.4980)	0.058 (0.4624)	-0.049 (0.4050)	0.073 (0.3975)	-0.055 (0.4455)
Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.050 (0.3890)	0.126 (0.5149)	0.023 (0.4225)	0.066 (0.4357)	0.085 (0.4287)
Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-0.112 (0.5501)	0.089 (0.5584)	0.060 (0.5910)	0.012 (0.4691)	0.066 (0.6085)
Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-0.110 (0.6778)	0.141 (0.6801)	0.007 (0.5926)	0.034 (0.6851)	0.095 (0.7994)
Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		-0.285 (0.6770)	0.023 (0.7253)	0.091 (0.8358)	-0.132 (0.8335)	0.039 (1.0454)
Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-0.233 (0.7281)	0.097 (0.8824)	0.014 (0.9236)	-0.118 (0.8440)	-0.067 (1.1713)
Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		-0.290 (0.8145)	-0.033 (0.9172)	0.029 (0.9819)	-0.035 (0.7013)	0.075 (1.0824)
Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-0.249 (1.0443)	0.108 (0.9947)	-0.057 (1.1804)	-0.097 (0.7284)	-0.007 (1.2338)
Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.103 (1.0101)	0.029 (0.7241)	-0.122 (1.1130)	-0.211 (0.8277)	0.020 (1.2950)
Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		0.003 (1.2619)	0.297 (0.8561)	0.058 (1.1522)	0.026 (0.7684)	0.167 (1.2472)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		-0.082 (1.3242)	0.237 (0.8722)	-0.093 (1.0792)	-0.248 (0.8581)	0.118 (1.1473)
Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		-0.170 (1.3453)	0.134 (0.8960)	-0.134 (1.2095)	-0.147 (0.8645)	0.034 (1.0839)
Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		0.097 (1.3103)	0.129 (0.8742)	-0.080 (1.1771)	-0.159 (0.7480)	0.108 (1.2532)
Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		0.137 (1.4139)	0.178 (0.9369)	-0.120 (1.1279)	-0.030 (0.7888)	0.140 (1.2161)

16. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume)
Description	Erythrocytes mean corpuscular volume was measured in femtolitres (fL).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: femtolitres (fL)
Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		0.422 (1.8855)	-0.087 (1.9540)	0.386 (2.2542)	-0.017 (2.1066)	-0.510 (2.7686)
Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		0.450 (1.8867)	-0.362 (2.1689)	-0.021 (1.8767)	-0.039 (2.3876)	-0.549 (2.5751)
Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		0.829 (2.3409)	-0.163 (2.4631)	0.945 (3.2325)	0.354 (2.8851)	-0.259 (2.5328)
Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		1.163 (3.6524)	0.938 (2.9445)	1.110 (3.0283)	0.916 (3.0058)	0.090 (3.5125)
Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		1.478 (3.9560)	0.951 (3.4617)	1.367 (3.8471)	0.342 (3.1129)	-0.390 (3.3907)
Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		1.107 (3.4022)	1.168 (3.7760)	1.571 (4.3326)	-0.016 (3.6944)	0.048 (4.4345)
Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		0.497 (3.5197)	-0.349 (2.8975)	0.649 (3.7758)	-0.338 (2.5959)	0.202 (4.2993)
Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-1.033 (2.9007)	-0.858 (2.1793)	0.143 (4.9985)	-1.522 (3.1692)	-1.195 (3.5759)
Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.910 (2.6477)	-1.184 (2.3264)	-0.754 (3.3662)	-1.854 (3.6605)	-1.638 (3.3447)
Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-1.654 (2.7565)	-1.851 (2.4024)	-1.075 (3.5390)	-2.071 (3.7652)	-2.351 (3.1052)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		-1.724 (3.1037)	-2.266 (2.3516)	-0.912 (3.9627)	-2.558 (3.8468)	-2.236 (3.2869)
Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		-1.386 (2.8575)	-1.882 (3.1285)	-1.698 (3.0263)	-2.885 (3.1443)	-2.421 (2.9445)
Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		-1.405 (3.4627)	-1.632 (3.4207)	-1.117 (3.4616)	-2.171 (4.4367)	-2.186 (3.4915)
Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		-0.942 (3.5913)	-1.492 (2.5065)	-0.846 (3.1243)	-1.527 (3.6540)	-1.788 (3.5554)

17. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Erythrocytes)
Description	Erythrocytes was measured in number of red blood cells per liter (10^12/L).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: 10^12 red blood cells per liter
Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.148 (0.2071)	-0.008 (0.1927)	0.050 (0.1773)	0.008 (0.2109)	-0.017 (0.1609)
Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.149 (0.2244)	-0.029 (0.1788)	-0.004 (0.2280)	-0.063 (0.2236)	0.000 (0.1809)
Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-0.132 (0.2780)	0.018 (0.2535)	0.023 (0.2135)	0.013 (0.1955)	0.031 (0.2065)
Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-0.135 (0.2546)	-0.011 (0.2206)	0.074 (0.2466)	0.014 (0.2190)	0.026 (0.2264)
Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		-0.131 (0.2678)	0.021 (0.2561)	0.069 (0.2419)	0.051 (0.2243)	0.075 (0.2393)
Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-0.020 (0.2375)	0.075 (0.2898)	0.047 (0.2810)	0.074 (0.2255)	0.110 (0.2533)
Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		0.036 (0.2618)	0.096 (0.2855)	0.068 (0.2089)	0.064 (0.2273)	0.081 (0.2191)
Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		0.059 (0.2639)	0.110 (0.2974)	0.142 (0.2573)	0.074 (0.2250)	0.110 (0.1931)
Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.034 (0.2453)	0.108 (0.2681)	0.122 (0.2445)	0.058 (0.2359)	0.106 (0.2567)
Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.010 (0.2461)	0.104 (0.2660)	0.133 (0.2716)	0.061 (0.2555)	0.156 (0.2714)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		0.044 (0.2524)	0.166 (0.2542)	0.156 (0.2849)	0.161 (0.2399)	0.145 (0.2377)
Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		0.079 (0.2682)	0.177 (0.2733)	0.163 (0.2736)	0.141 (0.2535)	0.129 (0.2403)
Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		0.035 (0.2645)	0.146 (0.2846)	0.133 (0.2622)	0.188 (0.2933)	0.135 (0.2128)
Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		0.061 (0.2693)	0.146 (0.2994)	0.141 (0.2747)	0.135 (0.2934)	0.129 (0.2354)

18. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Hematocrit)
Description	Hematocrit was measured in volume percentage (%) of red blood cells in blood.
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: volume % of red blood cells
Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-0.011 (0.0189)	-0.001 (0.0211)	0.007 (0.0181)	0.000 (0.0206)	-0.004 (0.0206)
Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.011 (0.0230)	-0.004 (0.0204)	-0.000 (0.0205)	-0.006 (0.0220)	-0.003 (0.0174)
Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-0.008 (0.0254)	0.001 (0.0211)	0.006 (0.0220)	0.003 (0.0190)	0.001 (0.0209)
Week 8	Number Analyzed	41 participants	39 participants	41 participants	38 participants	41 participants
		-0.007 (0.0239)	0.003 (0.0244)	0.012 (0.0237)	0.005 (0.0208)	0.003 (0.0232)
Week 12	Number Analyzed	41 participants	39 participants	43 participants	38 participants	41 participants
		-0.005 (0.0287)	0.007 (0.0281)	0.013 (0.0276)	0.006 (0.0219)	0.005 (0.0231)
Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		0.004 (0.0202)	0.012 (0.0259)	0.011 (0.0254)	0.006 (0.0240)	0.010 (0.0252)
Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		0.006 (0.0217)	0.007 (0.0270)	0.010 (0.0211)	0.004 (0.0241)	0.008 (0.0246)
Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		0.001 (0.0192)	0.006 (0.0253)	0.014 (0.0256)	-0.000 (0.0222)	0.005 (0.0219)
Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.007 (0.0210)	0.004 (0.0248)	0.008 (0.0241)	-0.003 (0.0229)	0.002 (0.0238)
Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-0.009 (0.0207)	0.000 (0.0249)	0.007 (0.0225)	-0.004 (0.0196)	0.003 (0.0248)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		-0.004 (0.0222)	0.004 (0.0228)	0.009 (0.0258)	0.003 (0.0221)	0.003 (0.0234)
Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		0.000 (0.0231)	0.007 (0.0278)	0.007 (0.0246)	-0.001 (0.0221)	0.000 (0.0206)
Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	36 participants
		-0.003 (0.0272)	0.006 (0.0297)	0.007 (0.0239)	0.007 (0.0246)	0.002 (0.0194)
Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	40 participants
		0.001 (0.0243)	0.007 (0.0257)	0.009 (0.0260)	0.005 (0.0252)	0.004 (0.0212)

19. Secondary Outcome

Title	Changes From Baseline in Hematology Parameters During the Study (Platelets)
Description	Platelets was measured in number of platelets per liter (10^9/L).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: 10^9 platelets per liter
Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-5.073 (30.2609)	-3.368 (25.9515)	3.209 (30.5883)	-2.098 (24.6412)	-9.325 (23.4109)
Week 2	Number Analyzed	42 participants	39 participants	42 participants	41 participants	41 participants
		4.000 (27.3112)	-5.179 (38.2800)	-3.810 (41.8250)	-15.122 (32.8414)	-15.415 (31.7025)
Week 4	Number Analyzed	41 participants	38 participants	41 participants	41 participants	41 participants
		-3.927 (29.6643)	-6.868 (29.7487)	-13.878 (43.7568)	-19.415 (32.6450)	-27.073 (41.9299)
Week 8	Number Analyzed	41 participants	39 participants	40 participants	38 participants	41 participants
		1.561 (29.1042)	-12.077 (28.9876)	-5.475 (44.7718)	-17.605 (29.8442)	-26.195 (44.1719)
Week 12	Number Analyzed	41 participants	39 participants	42 participants	38 participants	41 participants
		-2.171 (32.0795)	-17.359 (35.4308)	-11.286 (40.7451)	-10.079 (44.8977)	-23.171 (47.2995)
Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	40 participants
		-18.833 (50.4844)	-18.263 (37.3259)	-13.952 (50.7173)	-9.895 (35.3246)	-25.425 (37.6556)
Week 20	Number Analyzed	40 participants	39 participants	41 participants	37 participants	40 participants
		-18.625 (50.3988)	-23.077 (39.6534)	-10.512 (48.0755)	-15.324 (28.8329)	-22.725 (42.2502)
Week 24	Number Analyzed	39 participants	38 participants	40 participants	36 participants	40 participants
		-19.974 (49.0196)	-14.000 (37.7760)	-4.600 (49.4025)	-10.972 (36.8375)	-22.900 (47.4092)
Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-24.256 (51.8001)	-16.868 (40.6635)	-7.683 (47.8155)	-12.800 (30.7904)	-19.600 (42.3052)
Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-22.410 (51.9553)	-18.590 (41.7226)	-13.575 (51.9304)	-20.618 (38.8969)	-23.179 (42.2018)
Week 36	Number Analyzed	38 participants	38 participants	41 participants	33 participants	39 participants
		-25.000 (52.6990)	-16.474 (46.8844)	-14.561 (50.2106)	-18.848 (40.0563)	-23.846 (45.1340)
Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	38 participants
		-23.432 (53.2747)	-20.895 (41.4845)	-14.927 (51.2652)	-24.088 (33.4133)	-21.789 (46.1467)
Week 44	Number Analyzed	37 participants	38 participants	39 participants	34 participants	36 participants
		-22.703 (57.8383)	-22.474 (41.0627)	-18.051 (49.1646)	-24.735 (38.4710)	-31.389 (48.5306)
Week 48	Number Analyzed	38 participants	37 participants	41 participants	33 participants	39 participants
		-27.395 (56.2963)	-23.811 (47.1150)	-24.220 (46.2458)	-22.273 (37.4243)	-28.974 (42.9960)

20. Secondary Outcome

Title	Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)
Description	Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).
Time Frame	Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Outcome Measure Data

Analysis Population Description

The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Arm/Group Title		Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Arm/Group Description:		Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).	Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.	Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.
Overall Number of Participants Analyzed		42	39	43	41	41
Mean (Standard Deviation); Unit of Measure: U/L
Alanine Aminotransferase Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-1.366 (12.7451)	2.526 (15.5211)	2.628 (42.1234)	3.122 (10.2791)	0.700 (9.5868)
Alanine Aminotransferase Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-1.714 (15.4624)	2.026 (8.9428)	-1.047 (41.1223)	4.927 (20.9623)	1.171 (10.2978)
Alanine Aminotransferase Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-3.854 (15.1897)	1.553 (16.2758)	-3.952 (38.9546)	22.756 (139.8531)	-1.561 (10.1392)
Alanine Aminotransferase Week 8	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		-4.707 (13.6478)	-1.385 (9.4580)	5.465 (68.0764)	0.795 (11.4321)	-1.659 (11.1009)
Alanine Aminotransferase Week 12	Number Analyzed	41 participants	39 participants	42 participants	38 participants	41 participants
		-4.220 (15.1765)	0.359 (12.2356)	-4.429 (38.1756)	1.184 (13.0692)	-1.390 (8.1941)
Alanine Aminotransferase Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	41 participants
		-2.048 (18.0026)	2.684 (16.3229)	-4.857 (38.6211)	0.579 (12.9273)	0.829 (11.5432)
Alanine Aminotransferase Week 20	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		0.300 (39.9482)	3.821 (13.0139)	-4.881 (39.1808)	-0.838 (11.1118)	-1.350 (10.5479)
Alanine Aminotransferase Week 24	Number Analyzed	39 participants	38 participants	41 participants	36 participants	40 participants
		-1.564 (19.4974)	2.789 (14.5475)	-5.659 (39.6652)	1.528 (11.0259)	-3.475 (8.6202)
Alanine Aminotransferase Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-3.385 (17.7373)	2.658 (12.8174)	-3.244 (43.4688)	-0.171 (8.7228)	-2.775 (10.4280)
Alanine Aminotransferase Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-4.487 (16.5400)	2.385 (12.8956)	-4.150 (44.0126)	-2.176 (12.7742)	-0.821 (11.5482)
Alanine Aminotransferase Week 36	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		0.579 (10.5411)	0.184 (11.8660)	-2.976 (42.9275)	-0.471 (11.2848)	-1.103 (10.6296)
Alanine Aminotransferase Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	39 participants
		-0.622 (10.2506)	0.816 (12.6680)	-2.780 (44.9719)	-3.853 (11.1059)	-1.385 (13.1061)
Alanine Aminotransferase Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	39 participants
		2.649 (19.7993)	1.474 (13.1514)	-3.415 (43.2966)	-3.882 (12.8741)	-2.692 (10.2525)
Alanine Aminotransferase Week 48	Number Analyzed	38 participants	37 participants	41 participants	34 participants	40 participants
		2.605 (14.0646)	2.216 (12.8542)	-4.561 (43.1926)	-3.794 (13.1628)	-0.575 (9.6181)
Alkaline Phosphatase Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-1.098 (6.0034)	-1.342 (8.0983)	-2.721 (7.2056)	-3.244 (4.9989)	-4.275 (7.1360)
Alkaline Phosphatase Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-1.905 (6.7960)	-3.282 (7.8370)	-4.349 (9.5963)	-4.805 (7.8237)	-3.585 (8.8430)
Alkaline Phosphatase Week 4	Number Analyzed	41 participants	39 participants	42 participants	41 participants	41 participants
		-1.634 (9.0630)	-1.077 (10.4236)	-3.262 (9.9144)	-1.439 (18.3508)	-4.829 (10.9268)
Alkaline Phosphatase Week 8	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		-2.220 (8.3711)	0.308 (12.6515)	1.233 (37.8014)	-5.026 (10.2019)	-3.585 (9.8336)
Alkaline Phosphatase Week 12	Number Analyzed	41 participants	39 participants	42 participants	38 participants	41 participants
		-2.463 (8.8122)	-0.462 (12.1066)	-5.952 (11.0695)	-4.947 (12.0538)	-3.146 (17.2476)
Alkaline Phosphatase Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	41 participants
		-8.357 (12.7276)	-0.895 (13.1515)	-7.238 (10.7722)	-4.605 (11.6539)	-1.512 (25.7722)
Alkaline Phosphatase Week 20	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		-10.425 (14.0510)	-5.410 (15.1895)	-10.143 (13.0264)	-7.027 (11.8544)	-6.650 (14.8143)
Alkaline Phosphatase Week 24	Number Analyzed	39 participants	39 participants	41 participants	36 participants	40 participants
		-12.795 (15.4752)	-4.769 (13.8097)	-9.463 (11.3448)	-6.361 (12.7843)	-7.225 (18.4231)
Alkaline Phosphatase Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-12.795 (16.9351)	-5.684 (15.7259)	-11.244 (12.6249)	-8.314 (10.9054)	-8.525 (16.8523)
Alkaline Phosphatase Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-13.667 (16.1870)	-4.769 (16.1530)	-10.900 (13.0026)	-9.118 (12.5765)	-8.385 (17.5988)
Alkaline Phosphatase Week 36	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		-11.816 (19.2436)	-6.368 (15.4735)	-11.122 (12.3495)	-8.059 (9.5217)	-6.487 (19.2434)
Alkaline Phosphatase Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		-11.000 (16.9706)	-5.658 (15.7485)	-11.024 (12.9180)	-10.559 (11.6987)	-8.175 (17.8884)
Alkaline Phosphatase Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		-12.622 (17.6373)	-6.421 (14.9099)	-10.537 (13.5759)	-8.647 (10.5483)	-8.950 (18.3162)
Alkaline Phosphatase Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		-12.211 (19.0379)	-6.500 (16.5313)	-11.049 (14.4827)	-7.765 (12.3290)	-7.875 (20.1370)
Aspartate Aminotransferase Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-2.854 (10.3212)	1.447 (6.2155)	-0.023 (27.5409)	2.244 (6.7889)	0.475 (5.2963)
Aspartate Aminotransferase Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-1.762 (10.5294)	0.487 (4.0967)	-2.233 (26.3266)	3.805 (14.7635)	0.780 (6.1746)
Aspartate Aminotransferase Week 4	Number Analyzed	41 participants	38 participants	42 participants	41 participants	41 participants
		-3.976 (10.6642)	1.289 (7.5584)	-3.262 (25.1047)	8.927 (52.0660)	-1.195 (4.2791)
Aspartate Aminotransferase Week 8	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		-3.537 (10.5477)	-0.077 (5.8687)	2.279 (34.7805)	1.410 (5.5900)	0.366 (6.1877)
Aspartate Aminotransferase Week 12	Number Analyzed	41 participants	39 participants	42 participants	38 participants	41 participants
		-3.049 (12.2106)	0.436 (5.3054)	-2.595 (22.5324)	1.053 (6.9006)	1.122 (6.2897)
Aspartate Aminotransferase Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	41 participants
		-1.048 (12.1313)	2.974 (8.3649)	-2.595 (24.3852)	1.526 (6.6688)	2.122 (6.1733)
Aspartate Aminotransferase Week 20	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		6.375 (60.1309)	2.821 (6.6367)	-1.095 (25.1317)	1.324 (7.1065)	0.500 (4.8569)
Aspartate Aminotransferase Week 24	Number Analyzed	39 participants	38 participants	41 participants	36 participants	40 participants
		1.718 (23.7940)	2.237 (6.9182)	-1.902 (26.1054)	2.889 (6.2554)	0.325 (4.3759)
Aspartate Aminotransferase Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-1.179 (13.4905)	2.289 (6.9512)	-1.805 (27.4583)	2.229 (6.3063)	0.175 (4.1255)
Aspartate Aminotransferase Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		-1.385 (12.2895)	1.949 (6.2826)	-0.575 (28.3177)	0.324 (6.2654)	2.051 (4.9997)
Aspartate Aminotransferase Week 36	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		0.711 (7.3113)	1.026 (5.5140)	-1.220 (25.5798)	1.588 (6.6017)	1.667 (6.0755)
Aspartate Aminotransferase Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	39 participants
		0.946 (12.1494)	1.316 (5.5269)	0.244 (29.2701)	-0.647 (6.0597)	2.462 (8.4972)
Aspartate Aminotransferase Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	39 participants
		2.838 (15.4641)	2.553 (7.9175)	-1.268 (28.4280)	-0.588 (7.7190)	1.590 (6.9347)
Aspartate Aminotransferase Week 48	Number Analyzed	38 participants	37 participants	41 participants	34 participants	40 participants
		2.158 (9.7939)	3.459 (6.3403)	-1.927 (28.3182)	0.441 (6.6796)	2.900 (6.2339)
Gamma Glutamyl Transferase Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		0.171 (5.4447)	-2.737 (7.0354)	-0.535 (10.8745)	0.171 (5.0245)	-2.300 (6.2684)
Gamma Glutamyl Transferase Week 2	Number Analyzed	42 participants	39 participants	43 participants	41 participants	41 participants
		-0.190 (5.8736)	-2.026 (7.6828)	-4.116 (25.7527)	-0.341 (5.2517)	-1.268 (7.8773)
Gamma Glutamyl Transferase Week 4	Number Analyzed	41 participants	39 participants	42 participants	41 participants	41 participants
		-0.220 (7.2129)	-2.641 (9.9167)	-6.143 (35.5504)	1.171 (17.6265)	0.512 (16.3968)
Gamma Glutamyl Transferase Week 8	Number Analyzed	41 participants	39 participants	43 participants	39 participants	41 participants
		-1.829 (5.9745)	-4.410 (11.6319)	11.581 (103.8974)	-1.795 (5.7454)	-1.805 (9.0698)
Gamma Glutamyl Transferase Week 12	Number Analyzed	41 participants	39 participants	42 participants	38 participants	41 participants
		-0.585 (5.9033)	-2.154 (10.7643)	-5.762 (34.8767)	-0.447 (8.3785)	3.244 (21.8229)
Gamma Glutamyl Transferase Week 16	Number Analyzed	42 participants	38 participants	42 participants	38 participants	41 participants
		-0.357 (9.6445)	-1.842 (13.4476)	-4.357 (34.0020)	-0.947 (8.1868)	15.024 (77.1617)
Gamma Glutamyl Transferase Week 20	Number Analyzed	40 participants	39 participants	42 participants	37 participants	40 participants
		-0.750 (9.5051)	-2.769 (13.0555)	-5.452 (32.1970)	-1.649 (5.5137)	1.475 (22.2722)
Gamma Glutamyl Transferase Week 24	Number Analyzed	39 participants	39 participants	41 participants	36 participants	40 participants
		-0.615 (12.4173)	-2.769 (10.9339)	-4.122 (36.6832)	-2.639 (9.4360)	-2.625 (10.3272)
Gamma Glutamyl Transferase Week 28	Number Analyzed	39 participants	38 participants	41 participants	35 participants	40 participants
		-0.462 (11.5618)	-2.132 (11.7638)	-6.341 (36.7434)	-2.629 (7.6354)	-0.200 (11.5585)
Gamma Glutamyl Transferase Week 32	Number Analyzed	39 participants	39 participants	40 participants	34 participants	39 participants
		0.359 (15.7872)	-1.538 (13.2463)	-7.875 (36.9103)	-3.676 (8.6435)	2.795 (21.1501)
Gamma Glutamyl Transferase Week 36	Number Analyzed	38 participants	38 participants	41 participants	34 participants	39 participants
		-0.026 (14.7162)	-4.289 (11.4559)	-8.195 (38.6899)	-2.735 (7.1236)	1.410 (18.0200)
Gamma Glutamyl Transferase Week 40	Number Analyzed	37 participants	38 participants	41 participants	34 participants	40 participants
		-2.568 (9.3676)	-3.842 (13.9275)	-9.073 (40.5792)	-4.088 (7.5573)	0.925 (20.1066)
Gamma Glutamyl Transferase Week 44	Number Analyzed	37 participants	38 participants	41 participants	34 participants	39 participants
		1.081 (23.2108)	-1.289 (21.3730)	-7.488 (34.4145)	-3.824 (7.0430)	-0.949 (11.5643)
Gamma Glutamyl Transferase Week 48	Number Analyzed	38 participants	38 participants	41 participants	34 participants	40 participants
		1.474 (17.6723)	-2.184 (12.0850)	-7.805 (35.4924)	-2.941 (8.8247)	2.525 (20.6112)
Lactate Dehydrogenase Week 1	Number Analyzed	41 participants	38 participants	43 participants	41 participants	40 participants
		-7.000 (16.1509)	0.026 (19.6118)	-1.163 (33.1669)	-0.585 (16.6673)